{"id":"https://openalex.org/W2011880652","doi":"https://doi.org/10.3111/13696998.2015.1044457","title":"A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service","display_name":"A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service","publication_year":2015,"publication_date":"2015-04-23","ids":{"openalex":"https://openalex.org/W2011880652","doi":"https://doi.org/10.3111/13696998.2015.1044457","mag":"2011880652","pmid":"https://pubmed.ncbi.nlm.nih.gov/25903830"},"language":"en","primary_location":{"id":"doi:10.3111/13696998.2015.1044457","doi":"https://doi.org/10.3111/13696998.2015.1044457","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2015.1044457","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1044457?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1044457?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110180262","display_name":"K.Y. Westerhout","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094451","display_name":"Pharmerit (Netherlands)","ror":"https://ror.org/00ntr9f13","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210094451","https://openalex.org/I4210134090"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Kirsten Westerhout","raw_affiliation_strings":["a a Pharmerit , Rotterdam , The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a a Pharmerit , Rotterdam , The Netherlands","institution_ids":["https://openalex.org/I4210094451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108542558","display_name":"M. Treur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094451","display_name":"Pharmerit (Netherlands)","ror":"https://ror.org/00ntr9f13","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210094451","https://openalex.org/I4210134090"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Maarten Treur","raw_affiliation_strings":["a a Pharmerit , Rotterdam , The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a a Pharmerit , Rotterdam , The Netherlands","institution_ids":["https://openalex.org/I4210094451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111956387","display_name":"Angelika Mehnert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Angelika Mehnert","raw_affiliation_strings":["b b Janssen EMEA , Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"b b Janssen EMEA , Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049727249","display_name":"Katie C Pascoe","orcid":"https://orcid.org/0000-0001-5742-4654","observed_orcids":["https://orcid.org/0000-0001-5742-4654"]},"institutions":[{"id":"https://openalex.org/I4210118116","display_name":"Janssen (United Kingdom)","ror":"https://ror.org/02nw6hx08","country_code":"GB","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210118116"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Katie Pascoe","raw_affiliation_strings":["c c Janssen , High Wycombe UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"c c Janssen , High Wycombe UK","institution_ids":["https://openalex.org/I4210118116"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023929441","display_name":"Imran Ladha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118116","display_name":"Janssen (United Kingdom)","ror":"https://ror.org/02nw6hx08","country_code":"GB","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210118116"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Imran Ladha","raw_affiliation_strings":["c c Janssen , High Wycombe UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"c c Janssen , High Wycombe UK","institution_ids":["https://openalex.org/I4210118116"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089703907","display_name":"Jonathan Belsey","orcid":"https://orcid.org/0000-0001-7283-327X","observed_orcids":["https://orcid.org/0000-0001-7283-327X"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jonathan Belsey","raw_affiliation_strings":["d d JB Medical , Sudbury , UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"d d JB Medical , Sudbury , UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5089703907"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.4284,"has_fulltext":true,"cited_by_count":19,"citation_normalized_percentile":{"value":0.89186073,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"18","issue":"10","first_page":"838","last_page":"849"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.5615000128746033,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.5615000128746033,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.43700000643730164,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/simeprevir","display_name":"simeprevir","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hcv-genotype-1","display_name":"HCV genotype 1","score":0.8169999718666077},{"id":"https://openalex.org/keywords/pegylated-interferon","display_name":"pegylated interferon","score":0.6710000038146973},{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":1.0},{"id":"https://openalex.org/keywords/triple-therapy","display_name":"triple therapy","score":0.7070000171661377},{"id":"https://openalex.org/keywords/protease-inhibitors","display_name":"protease inhibitors","score":0.7580000162124634},{"id":"https://openalex.org/keywords/telaprevir","display_name":"telaprevir","score":0.9190000295639038},{"id":"https://openalex.org/keywords/boceprevir","display_name":"boceprevir","score":1.0},{"id":"https://openalex.org/keywords/cost-utility-analysis","display_name":"cost-utility analysis","score":0.8690000176429749},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9620000123977661},{"id":"https://openalex.org/keywords/sustained-virologic-response","display_name":"sustained virological response","score":0.9409999847412109},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.6380000114440918},{"id":"https://openalex.org/keywords/treatment-duration","display_name":"treatment duration","score":0.5759999752044678},{"id":"https://openalex.org/keywords/national-health-service","display_name":"National Health Service","score":0.625}],"concepts":[{"id":"https://openalex.org/C2778986448","wikidata":"https://www.wikidata.org/wiki/Q7517689","display_name":"Simeprevir","level":5,"score":0.9357060194015503},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8894138336181641},{"id":"https://openalex.org/C2778159067","wikidata":"https://www.wikidata.org/wiki/Q408557","display_name":"Telaprevir","level":5,"score":0.7462494969367981},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.7382227778434753},{"id":"https://openalex.org/C2777159539","wikidata":"https://www.wikidata.org/wiki/Q410551","display_name":"Boceprevir","level":5,"score":0.7073178291320801},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5209206938743591},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.46717673540115356},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.45799973607063293},{"id":"https://openalex.org/C2778390639","wikidata":"https://www.wikidata.org/wiki/Q2502747","display_name":"Sofosbuvir","level":5,"score":0.43785378336906433},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.43468180298805237},{"id":"https://openalex.org/C515549039","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost-effectiveness analysis","level":3,"score":0.4101574420928955},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.3894655704498291},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.27849340438842773},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.16511625051498413},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069616","descriptor_name":"Simeprevir","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069616","descriptor_name":"Simeprevir","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000069616","descriptor_name":"Simeprevir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006113","descriptor_name":"United Kingdom","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013222","descriptor_name":"State Medicine","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017063","descriptor_name":"Outcome Assessment, Health Care","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3111/13696998.2015.1044457","doi":"https://doi.org/10.3111/13696998.2015.1044457","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2015.1044457","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1044457?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:25903830","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25903830","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.3111/13696998.2015.1044457","doi":"https://doi.org/10.3111/13696998.2015.1044457","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2015.1044457","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2015.1044457?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2011880652.pdf","grobid_xml":"https://content.openalex.org/works/W2011880652.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W1593173821","https://openalex.org/W1789913733","https://openalex.org/W1874253413","https://openalex.org/W1970885621","https://openalex.org/W1972627455","https://openalex.org/W1977300462","https://openalex.org/W1983765304","https://openalex.org/W1984413237","https://openalex.org/W2003104968","https://openalex.org/W2016278419","https://openalex.org/W2027442554","https://openalex.org/W2027545702","https://openalex.org/W2027792646","https://openalex.org/W2035936208","https://openalex.org/W2041643208","https://openalex.org/W2052005188","https://openalex.org/W2053797606","https://openalex.org/W2063966947","https://openalex.org/W2068790832","https://openalex.org/W2082508303","https://openalex.org/W2094174828","https://openalex.org/W2094630798","https://openalex.org/W2094972821","https://openalex.org/W2114323000","https://openalex.org/W2127189337","https://openalex.org/W2131011125","https://openalex.org/W2132290252","https://openalex.org/W2137052325","https://openalex.org/W2143244227","https://openalex.org/W2153429965","https://openalex.org/W2161668598","https://openalex.org/W2313300349"],"related_works":["https://openalex.org/W2092015313","https://openalex.org/W1993580270","https://openalex.org/W4248230003","https://openalex.org/W2189194747","https://openalex.org/W2317638828","https://openalex.org/W2334551942","https://openalex.org/W3030679806","https://openalex.org/W1891391480","https://openalex.org/W2180280393","https://openalex.org/W2000699183"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Triple":[1],"therapy":[2,92],"using":[3],"a":[4,40,100,111,142,154,283],"protease":[5],"inhibitor":[6],"(PI)":[7],"with":[8,18,39,66,75,225,257,260,290],"peginterferon":[9],"and":[10,135,158,166,184,212,237],"ribavirin":[11],"(PR)":[12],"is":[13],"increasingly":[14],"used":[15],"in":[16,64,72,93,241],"patients":[17,73,289],"chronic":[19,291],"hepatitis":[20],"C":[21],"virus":[22],"(HCV)":[23],"infection.":[24,295],"The":[25,46,177,196],"most":[26],"recently":[27],"introduced":[28],"PI,":[29],"simeprevir":[30],"(SMV),":[31],"offers":[32],"high":[33],"levels":[34],"of":[35,44,48,56,91,153,189,208,222,251,255],"viral":[36,113],"eradication":[37],"combined":[38,259],"reduced":[41,267],"overall":[42,262],"duration":[43],"therapy.":[45],"objective":[47],"this":[49],"study":[50],"was":[51,83,187,217],"to":[52,109,266,273],"compare":[53],"the":[54,89,126,185,190,248],"cost-effectiveness":[55],"SMV":[57,202,230,279],"+":[58,203,231,235,239,280],"PR":[59,61,204,206,232,236,240,281],"vs":[60,205],"alone":[62,207],"or":[63,69],"combination":[65],"telaprevir":[67],"(TVR)":[68],"boceprevir":[70],"(BOC)":[71],"infected":[74],"genotype":[76,292],"1":[77,293],"HCV":[78,156,294],"Method:":[79],"A":[80],"cost-utility":[81],"model":[82,178,197],"constructed,":[84],"incorporating":[85],"two":[86],"phases,":[87],"capturing":[88,105],"efficacy":[90],"an":[94,151,199,252],"initial":[95],"treatment":[96,144,269,277,286],"phase,":[97,104],"followed":[98],"by":[99,219],"long-term":[101,227],"post-treatment":[102],"Markov":[103],"lifetime":[106],"outcomes":[107],"according":[108],"whether":[110],"sustained":[112],"response":[114],"(SVR)":[115],"had":[116],"been":[117],"achieved":[118],"on":[119,125],"treatment.":[120,132],"Dosage":[121],"regimens":[122],"were":[123,139,148,170],"based":[124],"EMA":[127],"approved":[128],"label":[129],"for":[130,201,210,214,288],"each":[131],"SVR":[133,256],"estimates":[134],"adverse":[136],"event":[137],"rates":[138],"derived":[140],"from":[141,150,172],"mixed":[143],"comparison.":[145],"Baseline":[146],"characteristics":[147],"drawn":[149,171],"analysis":[152],"UK":[155,191],"data-set":[157],"clinician":[159],"opinion.":[160],"Health":[161,193],"state":[162,168],"transition":[163],"probabilities,":[164],"utilities,":[165],"health":[167,181],"costs":[169,182],"previously":[173],"published":[174],"economic":[175],"analyses.":[176],"considered":[179],"direct":[180],"only,":[183],"perspective":[186],"that":[188],"National":[192],"Service.":[194],"RESULTS:":[195],"yielded":[198],"ICER":[200],"\u00a39725/QALY":[209],"treatment-na\u00efve":[211],"\u00a37819/QALY":[213],"treatment-experienced.":[215],"Benefit":[216],"driven":[218],"increased":[220,253],"likelihood":[221,254],"achieving":[223],"SVR,":[224],"consequent":[226],"utility":[228],"gains.":[229],"dominated":[233],"TVR":[234],"BOC":[238],"both":[242],"patient":[243],"groups.":[244],"This":[245],"principally":[246],"reflected":[247],"QALY":[249],"benefit":[250],"SMV,":[258],"lower":[261],"drug":[263],"costs,":[264],"due":[265],"mean":[268],"duration.":[270],"CONCLUSION:":[271],"Compared":[272],"other":[274],"currently":[275],"licensed":[276],"options,":[278],"represents":[282],"cost":[284],"effective":[285],"option":[287]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}